CVM-Pharmacy Spring Symposium What CVM has to Offer (Oncology) ( ACCR)

1. CVM-Pharmacy Spring Symposium What CVM has to Offer (Oncology) (ACCR) Jaime F. Modiano

2. The Animal Cancer Care and Research Program (ACCR) • Joint program of CVM and MCC • Basic, translational, and clinical research mission • Educational and training mission • Clinical service delivery mission

3. Onc Section Faculty and Research Interests Jaime Modiano – Professor Cancer biology, immunology, genetics Mike Henson – Associate Professor Translational therapy Fekadu Kassie – Assistant Professor Cancer chemoprevention Erin Dickerson – Assistant Professor Drug targeting and cancer metabolism Antonella Borgatti – Assistant Professor Translational therapy Daisuke Ito – Assistant Professor (6/1/13) Lymphoma biology Claire Cannon – Research Associate (Onc Fellow) Translational therapy

4. Other ACCR Faculty Liz Pluhar and Vicki Wilke (CVM, Surgery) Subree Subramanian (SOM - Surgery) Aaron Sarver (MCC) David Largaespada (MCDBG) Khalil Ahmed (VA and SOM, LMP) Jeff Miller (SOM, Medicine) Dan Vallera (SOM, Radiology) Many others

5. Research Opportunities > 1 million dogs are diagnosed and managed with cancer in the U.S. each year Intact immune system Compressed life span Cancers are influenced by similar factors (e.g. age, nutrition, gender, reproductive state, environmental exposure) www.canusgoatsmilk.com

6. Key Programs Brain cancer (Pluhar, Moertel) Sarcomas (Borgatti, Weigel, Largaespada, Spector, Wilke, Sarver, Subramanian, Modiano, Dickerson, Clohisy, et. al.) Hematologic malignancies (Ito, Miller, Modiano, O’Brien, Linden, Bachanova, Burns) Chemical carcinogenesis and prevention (Kassie) Etiology and cancer genetics (Modiano, Sarver, Subramanian, Largaespada, O’Brien, Kassie) Therapeutic targeting and microRNAs (Subramanian, Dickerson, Vallera, Ahmed, Kassie) Clinical trials (Borgatti, Henson, Cannon)

7. Resources • Tissue bank • >100 cell lines (mostly sarcomas) and >1200 tumor samples with blood for germ line DNA (e.g., T:N sequencing) with broad geographic distribution • Bank was developed as a joint effort with collaborators at Broad and NCSU, and supplemented from local patient samples and from U of M clinical studies

8. Clinical Opportunities Studies originating locally (home grown therapies) Studies originating from contracts or collaborations (imported technology) Hypothesis testing and hypothesis generating

10. Tumor Distribution at the CVMAll Admissions

12. Tumor Distribution at the CVMNew Diagnoses

14. - New Diagnoses

16. Clinical Oncology Studies at the CVM Disease Study Description Inclusion/exclusion Incentive PI Status

17. Clinical Oncology Studies at the CVM Disease Study Description Inclusion/exclusion Incentive PI Status

18. Clinical Oncology Studies at the CVM Disease Study Description Inclusion/exclusion Incentive PI Status

19. Clinical Investigation Center (CIC)

20. What Else Sets the UMN Apart? A Few Select Examples: • Translation of brain cancer therapy from dogs to humans • “Successful Cancer Trial In Dogs Helping To Save Teenager” • Prediction and prognosis for bone cancer patients • “U of M researchers look to dogs to better understand intricacies of bone cancer” • Translation of cancer therapies from humans to dogs and back • Sal-IL-2 for bone cancer • Minnelide™ for bone cancer • “LICKing Lymphoma” – Novartis partnership targeting tumor initiating cells • Bispecific Ligand Targeted Toxin for hemangiosarcoma • Gene therapy for liver tumors

21. What Have We Accomplished? Research success has allowed us to establish a level of credibility in the scientific community and created a stable partnership between CVM and MCC Success stories extend from the laboratory to the clinic – advancing translation